L-asparaginase: New about Well-Known Drug
The history of asparaginase clinical use is inextricably linked to the improvement of treatment programs for acute lymphoblastic leukaemia (ALL). Asparaginase, obtained from E. coli, has become the crucial part in the protocols for the treatment of ALL in children and adults since the 1960s-1970s du...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2021-07-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/2017 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849695739476705280 |
|---|---|
| author | Yuliya S. Korkina Timur T. Valiev |
| author_facet | Yuliya S. Korkina Timur T. Valiev |
| author_sort | Yuliya S. Korkina |
| collection | DOAJ |
| description | The history of asparaginase clinical use is inextricably linked to the improvement of treatment programs for acute lymphoblastic leukaemia (ALL). Asparaginase, obtained from E. coli, has become the crucial part in the protocols for the treatment of ALL in children and adults since the 1960s-1970s due to its antitumor effect on lymphoid leukemia cells. Despite the evolution of therapeutic approaches in ALL management, changes in used chemotherapeutic agents, their administration regimens and doses, the asparaginase remains one of the leading therapeutic agents in ALL patients. With time ideas about the asparaginase mechanisms have expanded, new data have been accumulated on adverse effects (allergic reactions, thrombotic complications, pancreatitis, hepatic dysfunction, etc.). The asparaginase obtained from Erwinia chrysanthemi and PEGylated forms of the drug were used to reduce the frequency of any of such adverse effects. This literature review provides current concepts on the mechanism of L-asparaginase dosage forms action, describes side effects associated with the use of this medication. We also present our own clinical case of L-asparaginase (obtained from Erwinia chrysanthemi) administration in ALL patient with allergic reaction to PEG-L-asparaginase. |
| format | Article |
| id | doaj-art-01b181982cc04883ac8d7fb3b4eee70b |
| institution | DOAJ |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2021-07-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-01b181982cc04883ac8d7fb3b4eee70b2025-08-20T03:19:41ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892021-07-0118322723210.15690/pf.v18i3.22821807L-asparaginase: New about Well-Known DrugYuliya S. Korkina0Timur T. Valiev1Russian Medical Academy of Continuing Professional EducationNational Medical Research Center of Oncology named after N.N. BlokhinThe history of asparaginase clinical use is inextricably linked to the improvement of treatment programs for acute lymphoblastic leukaemia (ALL). Asparaginase, obtained from E. coli, has become the crucial part in the protocols for the treatment of ALL in children and adults since the 1960s-1970s due to its antitumor effect on lymphoid leukemia cells. Despite the evolution of therapeutic approaches in ALL management, changes in used chemotherapeutic agents, their administration regimens and doses, the asparaginase remains one of the leading therapeutic agents in ALL patients. With time ideas about the asparaginase mechanisms have expanded, new data have been accumulated on adverse effects (allergic reactions, thrombotic complications, pancreatitis, hepatic dysfunction, etc.). The asparaginase obtained from Erwinia chrysanthemi and PEGylated forms of the drug were used to reduce the frequency of any of such adverse effects. This literature review provides current concepts on the mechanism of L-asparaginase dosage forms action, describes side effects associated with the use of this medication. We also present our own clinical case of L-asparaginase (obtained from Erwinia chrysanthemi) administration in ALL patient with allergic reaction to PEG-L-asparaginase.https://www.pedpharma.ru/jour/article/view/2017asparaginasepeg-asparaginaseerwinaseacute lymphoblastic leukaemiatreatment |
| spellingShingle | Yuliya S. Korkina Timur T. Valiev L-asparaginase: New about Well-Known Drug Педиатрическая фармакология asparaginase peg-asparaginase erwinase acute lymphoblastic leukaemia treatment |
| title | L-asparaginase: New about Well-Known Drug |
| title_full | L-asparaginase: New about Well-Known Drug |
| title_fullStr | L-asparaginase: New about Well-Known Drug |
| title_full_unstemmed | L-asparaginase: New about Well-Known Drug |
| title_short | L-asparaginase: New about Well-Known Drug |
| title_sort | l asparaginase new about well known drug |
| topic | asparaginase peg-asparaginase erwinase acute lymphoblastic leukaemia treatment |
| url | https://www.pedpharma.ru/jour/article/view/2017 |
| work_keys_str_mv | AT yuliyaskorkina lasparaginasenewaboutwellknowndrug AT timurtvaliev lasparaginasenewaboutwellknowndrug |